In the present study, the potential use of the CELx HSP test was investigated to quantitatively assess the dynamic status of the HER2 signaling network in patient-derived live primary breast tumor cells from patients classified as HER2− by traditional IHC and or FISH-based clinical pathology tests. This evidence concerns the gene ERBB2 and breast neoplasm.